In addition, although T-DXd is quickly becoming the drug of choice for the treatment of HER2-positive breast cancer, neutropenia and interstitial lung disease (ILD) are T-DXd-related adverse events that have been associated with some risks for treatment-related fatality [95]. Here, ERBB2 is linked to interstitial lung disease.